Ocular Inflammation
📧 Sign up to get email alerts when something new happens for Ocular Inflammation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-09-03Clinical Trial Update: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]
Phase 3 trial results for mapracorat ophthalmic suspension 3% in treating ocular inflammation and pain after cataract surgery have been comp…
-
CLINICAL_TRIALS trial_result · 2020-04-14Clinical Trial Update: LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]
Phase 3 trial update for LE Gel in treating ocular inflammation and pain after cataract surgery has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-04-07Clinical Trial Update: KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children [Phase 3]
Phase 3 trial comparing KPI-121 1% to prednisolone for ocular inflammation after pediatric cataract surgery was terminated; results posted i…
-
FDA approval · 2020-03-02FDA Approved: DEXTENZA — Supplemental Application (Ocular Therapeutix, Inc.)
FDA approved a supplemental application for DEXTENZA (dexamethasone) submitted by Ocular Therapeutix, Inc., related to its labeling for ocul…
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. [Phase 4]
Phase 4 trial evaluating PRO-155 for inflammation of the conjunctival surface in Grade I-III pterygium versus placebo; results posted after …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2019-05-17Clinical Trial Update: Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease [Phase 4]
A Phase 4 clinical trial investigating the effects of Xiidra on closed-eye tear film leukocytes in dry eye disease was withdrawn.
-
FDA approval · 2019-02-22FDA Approved: LOTEMAX SM — Original Application (Bausch & Lomb Incorporated)
The FDA approved LOTEMAX SM (loteprednol etabonate) ophthalmic gel under its original application (NDA 208219) from Bausch & Lomb. It is ind…
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery [Phase 2]
Phase 2 trial evaluating efficacy and safety of RX-10045 ophthalmic solution for ocular inflammation and pain after cataract surgery; result…
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery [NA]
A completed clinical trial comparing bromfenac 0.07% once daily to nepafenac 0.3% once daily for ocular inflammation after cataract surgery,…
-
CLINICAL_TRIALS trial_result · 2018-10-22Clinical Trial Update: Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Clinical trial update reporting outcomes of Lotemax 0.5% for ocular inflammation after cataract surgery in pseudophakia patients; results po…
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: PGE2 Levels in Patient Treated With NSAIDs [Phase 3]
Phase 3 clinical trial update on PGE2 levels in patients treated with NSAIDs for ocular inflammation. The study status is completed.
-
FDA approval · 2018-06-06FDA Approved: PRED FORTE — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for PRED FORTE (prednisolone acetate ophthalmic suspension) submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2017-04-27Clinical Trial Update: Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery [Phase 2]
Phase II study evaluating safety and efficacy of OTX-DP for ocular inflammation and pain after cataract surgery has completed with results p…
-
CLINICAL_TRIALS trial_result · 2017-01-24Clinical Trial Update: Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation [Phase 3]
Phase 3 clinical trial results evaluating XG-102 for reducing post-cataract surgery intraocular inflammation have been completed, with repor…
-
CLINICAL_TRIALS trial_result · 2017-01-24Clinical Trial Update: Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain [Phase 3]
Phase 3 trial of XG-102 for reducing post-cataract surgery intraocular inflammation and pain has completed, evaluating efficacy and safety.
-
FDA approval · 2016-08-05FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)
The FDA approved a supplemental application for MAXIDEX (dexamethasone) from Harrow Eye, LLC, authorizing changes to the drug's labeling as …
-
CLINICAL_TRIALS trial_result · 2016-07-13Clinical Trial Update: Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects [Phase 3]
Phase 3 trial comparing ISV-303 to DuraSite vehicle in ocular inflammation after cataract surgery completed with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-07-13Clinical Trial Update: Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers [Phase 1, Phase 2]
A phase 1/2 trial comparing dosing regimens of ISV-303 (bromfenac in DuraSite) to Xibrom and vehicle in ocular inflammation following catara…
-
CLINICAL_TRIALS trial_result · 2016-07-13Clinical Trial Update: Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects [Phase 3]
Phase 3 trial comparing ISV-303 to Durasite vehicle in cataract surgery patients with ocular inflammation has completed with results posted …
-
FDA approval · 2016-04-11FDA Approved: DIFLUPREDNATE OPHTHALMIC — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for difluprednate ophthalmic submitted by Sandoz Inc, resulting in updated labeling for the product.
-
CLINICAL_TRIALS withdrawal · 2014-12-11Clinical Trial Update: Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection [Phase 3]
A Phase 3 trial evaluating an antibiotic–steroid ophthalmic combination vs its individual components for ocular inflammation and infection w…
-
FDA approval · 2013-12-16FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (Bausch & Lomb Americas Inc.)
The FDA approved a supplemental application for Loteprednol Etabonate (Lotemax) from Bausch & Lomb Americas Inc.
-
CLINICAL_TRIALS trial_result · 2013-09-18Clinical Trial Update: Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients [Phase 2]
Phase 2 trial of IBI-10090 in ocular inflammation associated with cataract surgery was terminated; results were posted in 2013.
-
FDA approval · 2013-04-05FDA Approved: BROMFENAC OPHTHALMIC SOLUTION — Original Application (Bausch & Lomb Americas Inc.)
FDA approved Bromfenac ophthalmic solution (bromfenac sodium) from Bausch & Lomb Americas Inc. as an original NDA. It is indicated for relie…
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery [Phase 3]
Phase 3 trial update evaluating the safety and efficacy of bromfenac ophthalmic solution for reducing ocular inflammation and pain after cat…